A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

17300

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)

Interventions

DRUG: Lepodisiran Sodium
DRUG: Placebo

Sponsor

Eli Lilly and Company